Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat model
Moreno, O; Fernández, I; Plaza-García, S; Padro, D; Baz, Z; Ramos-Cabrer, P; Martín, A; Llop, J.
NeuroImage, 2026, , 121753
Aggregation Issues in Radioactive Copper-Labeled Antibodies
Zeeshan, M; Nguyen, HB; Yoo, J
Nucl. Med. Molec. Imag., 2025,10.1007/s13139-025-00974-6
One‐pot Base‐free Suzuki‐Miyaura [11C]Methylation: Kinetic and Mechanistic Insights
Moreno, O; Azzeggarh, I; Holland, JP; Windhorst, AD; Llop, J.
Chem. Eur. J., 2025,10.1002/chem.202503251
Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer's disease brain are associated with Abeta, tau pathologies and synaptic loss.
Maschio, CA; Moreno, O; Wang, J; Maheshwari, U; Keller, A; Konietzko, U; Razansky, D; Nordberg, A; Rominger, A; Hock, C; Llop, J; Nitsch, RM; Ni, R
Alzheimer's Res. Ther., 2025,10.1186/s13195-025-01916-2
Biomarkers for prediction of chronic traumatic encephalopathy-like pathology following repeated mild traumatic brain injury in rats are partially sex- and age-dependent.
Moraga-Amaro, R; Moreno, O; Llop, J; Bankstahl, M; Bankstahl, JP
Exp Neurol, 2025, , 115560
Longitudinal imaging evaluation of the inflammatory role of purinergic A2A receptors during subacute and chronic ischemic stroke
Garbizu, M; Mocha-Munoz, N; Rubio-Lopez, E; Palacios, L; Aguado, L; Ardaya, M; Joya, A; Alduntzin, U; Plaza-Garcia, S; Padro, D; Gomez-Vallejo, V; Cossio, U; Higuchi, M; Ramos-Cabrer, P; Zugaza, JL; Llop, J; Martin, A
J. Cereb. Blood Flow Metab., 2025,10.1177/0271678X251370835
Unravelling the role of L- and D- alanine in prostate cancer: a Positron Emission Tomography study in a genetic mouse model
Castellnou, P; Gómez-Martínez, M; Gómez-Vallejo, V; Baz, Z; López-Gallego, F; Rondon-Lorefice, I; Zabala-Letona, A; Poot, AJ; Mendizabal, I; Carracedo, A; Rejc, L; Llop, J.
Nucl Med Biol, 2025, 148-149, 109048
Chronic treatment with adenosine A1 receptor antagonist promotes neurogenesis and improves outcome after cerebral ischemia.
Ardaya, M; Benito-Munoz, M; Rubio-Lopez, E; Garbizu, M; Aguado, L; Mocha-Munoz, N; Iglesias, L; Aldutzin, U; Matute, C; Soria, FN; Gomez-Vallejo, V; Garcia-Etxarri, A; Llop, J; Cavaliere, F; Martin, A
J. Cereb. Blood Flow Metab., 2025, , 271678X251345294
P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice
Alves, M; de Diego-Garcia, L; Vegliante, G; Moreno, O; Gil, B; Ramos-Cabrer, P; Mitra, M; Martin, AF; Menéndez-Méndez, A; Wang, Y; Strogulski, NR; Sun, M; Melia, C; Conte, G; Plaza-García, S; Khalin, I; Teng, X; Plesnila, N; Klebl, B; Dinkel, K; Hamacher, M; Bhattacharya, A; Ceusters, M; Palmer, J; Loane, DJ; Llop, J; Henshall, DC; Engel, T.
Theranostics, 2025, 15, 1399-1419
Short- and long-term changes in neurological, behavioural, and blood biomarkers following repeated mild traumatic brain injury in rats-potential biological sex-dependent effects.
Moraga-Amaro, R; Moreno, O; Llop, J; Bankstahl, M; Bankstahl, JP
Front. mol. neurosci, 2025, 18, 1488261
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.
Choi, H; Jeong, SH; Simo, C; Bakenecker, A; Llop, J; Lee, HS; Kim, TY; Kwak, C; Koh, GY; Sanchez, S; Hahn, SK
Nat. Commun., 2024, 15, 9934
Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke
Pérez-Mato, M; Dopico-Lopez, A; Akkoc, Y; López-Amoedo, S; Correa-Paz, C; Candamo-Lourido, M; Iglesias-Rey, R; López-Arias, E; da Silva-Candal, A; Bravo, SB; Chantada-Vázquez, MD; Arias, S; Santamaría-Cadavid, M; Estany-Gestal, A; Zaghmi, A; Gauthier, MA; Gutierrez-Fernandez, M; Martin, A; Llop, J; Rodríguez, C; Almeida, A; Migliavacca, M; Polo, E; Pelaz, B; Gozuacik, D; El Yamani, N; SenGupta, T; Rundén-Pran, E; Vivancos, J; Castellanos, M; Díez-Tejedor, E; Sobrino, T; Rabinkov, A; Mirelman, D; Castillo, J; Campos, F
iScience, 2024, 27, 111108